Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

Summary

This is an open-label, single-arm, multicenter, exploratory Phase II study sponsored by Astrazeneca Investment (China) Co., LTD. to evaluate the efficacy and safety of Osimertinib with Platinum plus Pemetrexed Chemotherapy, as First-line Treatment in Recurrent or Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients with Uncommon Epidermal Growth Factor Receptor Mutations (EGFRm).

Timeline

Start

2022-01-19

Primary completion

2023-03-09

Completion

2023-03-09

Drugs

Indications